TXMD,UTHR Stock Price and Quote

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change +0.04
Percentage change 2.88	%

Peers: VERU SNDX ARCT TGTX ONCY ATNM VRCA IBRX HRTG GNPX

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-0.19	Insider Own	2.03%	Shs Outstand	11.53M	Perf Week	24.35%
Market Cap	16.55M	Forward P/E	-	EPS next Y	-	Insider Trans	1.35%	Shs Float	11.34M	Perf Month	43.00%
Income	-2.18M	PEG	-	EPS next Q	-	Inst Own	30.50%	Short Float	1.29%	Perf Quarter	32.41%
Sales	1.76M	P/S	9.41	EPS this Y	-	Inst Trans	9.15%	Short Ratio	0.50	Perf Half Y	-8.92%
Book/sh	2.37	P/B	0.60	EPS next Y	-	ROA	-5.63%	Short Interest	0.15M	Perf Year	-23.94%
Cash/sh	0.44	P/C	3.27	EPS next 5Y	-	ROE	-8.16%	52W Range	0.70 - 2.44	Perf YTD	66.28%
Dividend Est.	-	P/FCF	22.68	EPS past 5Y	64.95%	ROI	-6.63%	52W High	-41.39%	Beta	0.57
Dividend TTM	-	Quick Ratio	1.92	Sales past 5Y	498.17%	Gross Margin	71.10%	52W Low	104.29%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	1.92	EPS Y/Y TTM	81.05%	Oper. Margin	-198.30%	RSI (14)	77.84	Volatility	10.18% 9.84%
Employees	1	Debt/Eq	0.26	Sales Y/Y TTM	35.25%	Profit Margin	-123.85%	Recom	3.00	Target Price	5.00
Option/Short	Yes / Yes	LT Debt/Eq	0.20	EPS Q/Q	128.46%	Payout	-	Rel Volume	0.31	Prev Close	1.39
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	32.87%	Earnings	Mar 27 AMC	Avg Volume	293.01K	Price	1.43
SMA20	33.15%	SMA50	48.13%	SMA200	7.28%	Trades		Volume	76,726	Change	2.88%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-07-20	Downgrade	Jefferies	Hold → Underperform
May-19-20	Downgrade	JP Morgan	Overweight → Neutral
Dec-02-19	Initiated	Guggenheim	Buy
Oct-17-19	Initiated	H.C. Wainwright	Buy	$7
Apr-30-19	Resumed	Noble Capital Markets	Outperform	$13
Jun-15-18	Initiated	JP Morgan	Overweight	$11
Sep-08-17	Initiated	Morgan Stanley	Equal-Weight	$6
Jul-11-17	Upgrade	Oppenheimer	Perform → Outperform
May-09-17	Downgrade	Oppenheimer	Outperform → Perform
Nov-22-16	Resumed	Jefferies	Buy	$18
Nov-22-16	Initiated	Oppenheimer	Outperform
Nov-07-16	Resumed	Guggenheim	Buy
Apr-04-16	Initiated	Goldman	Buy	$10
Dec-08-15	Reiterated	Stifel	Buy	$10 → $14
Dec-08-15	Reiterated	Jefferies	Buy	$15 → $18
Sep-21-15	Reiterated	Jefferies	Buy	$7 → $15
Jun-09-15	Initiated	Guggenheim	Buy
Jul-08-14	Initiated	FBR Capital	Outperform	$34
Apr-17-14	Reiterated	Noble Financial	Buy	$9 → $13
Jan-28-14	Reiterated	Noble Financial	Buy	$7.25 → $9

Show Previous Ratings

Mar-27-25 04:05PM	TherapeuticsMD Announces Full Year 2024 Financial Results (Business Wire) -6.48%
Nov-12-24 04:32PM	TherapeuticsMD: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	TherapeuticsMD Announces Third Quarter 2024 Financial Results (Business Wire)
Aug-12-24 05:26PM	TherapeuticsMD: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	TherapeuticsMD Announces Second Quarter 2024 Financial Results (Business Wire)
11:52AM	Loading…
Jun-28-24 11:52AM	TXMD Stock Earnings: TherapeuticsMD Reported Results for Q4 2023 (InvestorPlace) -7.47%
May-10-24 08:53PM	TXMD Stock Earnings: TherapeuticsMD Reported Results for Q1 2024 (InvestorPlace)
04:43PM	TherapeuticsMD: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	TherapeuticsMD Announces First Quarter 2024 Financial Results (Business Wire)
Mar-29-24 04:00PM	TherapeuticsMD Announces Full Year 2023 Financial Results (Business Wire)
Mar-12-24 11:40AM	25 Countries With Highest Abortion Rates (Insider Monkey) +6.95%
Jan-30-24 11:20PM	12 Best Prenatal Vitamins For Pregnant Women (Insider Monkey)
Nov-15-23 05:08AM	TherapeuticsMD: Q3 Earnings Snapshot (Associated Press Finance) +17.41%
Nov-14-23 04:05PM	TherapeuticsMD Announces Third Quarter 2023 Financial Results (Business Wire)
Aug-14-23 07:52AM	TherapeuticsMD: Q2 Earnings Snapshot (Associated Press Finance)
06:50AM	Loading…
06:50AM	TherapeuticsMD Announces Second Quarter 2023 Financial Results (Business Wire)
May-15-23 05:56PM	TherapeuticsMD: Q1 Earnings Snapshot (AP Finance)
04:05PM	TherapeuticsMD Announces First Quarter 2023 Financial Results (Business Wire)
Apr-14-23 12:00PM	All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy (Zacks)
Apr-07-23 04:01PM	TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition (Business Wire)
Jan-03-23 06:50AM	TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma (Business Wire) +11.81%
Dec-08-22 10:42AM	Boca pharma company will cut 212 employees after failed buyout (American City Business Journals)
Dec-04-22 06:00PM	TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma (Business Wire)
Nov-14-22 07:55PM	TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -7.45% -8.20%
04:05PM	TherapeuticsMD Announces Third Quarter 2022 Financial Results (Business Wire)
Oct-31-22 06:50AM	TherapeuticsMD Announces Additional $7 Million Private Placement (Business Wire) +6.21%
Oct-03-22 01:45PM	TherapeuticsMD receives $7M investment after merger plans unravel (American City Business Journals) -7.53%
06:50AM	TherapeuticsMD Announces $7 Million Private Placement (Business Wire)
Sep-12-22 06:50AM	TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers (Business Wire) +5.55%
Aug-15-22 01:00PM	TherapeuticsMD, Inc. (TXMD) Q2 2022 Earnings Call Transcript (Motley Fool)
08:05AM	Loading…
08:05AM	TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:50AM	TherapeuticsMD Announces Second Quarter 2022 Financial Results (Business Wire)
Aug-08-22 06:50AM	TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022 (Business Wire)
Aug-01-22 01:00PM	Pharma firm receives $15M investment after canceled merger (American City Business Journals) +36.60%
06:50AM	TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital (Business Wire)
Jul-15-22 01:34PM	HC Wainwright Rating & Price Target On TherapeuticsMD Under Review On 'Unclear Path' (Benzinga) +12.50%
Jul-13-22 09:48AM	Why TherapeuticsMD Shares Are Sinking Today? (Benzinga) -35.55%
08:25AM	TherapeuticsMD's stock falls 41% after tender offer expires (MarketWatch)
06:50AM	TherapeuticsMD Announces Expiration of Tender Offer (Business Wire)
Jul-06-22 06:09AM	EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer (PR Newswire)
Jun-06-22 04:05PM	EW Healthcare Partners Announces Commencement of the Tender Offer for All Outstanding Shares of TherapeuticsMD (PR Newswire)
May-31-22 06:00AM	TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD (Business Wire) +364.02%
May-20-22 10:52AM	Why TherapeuticsMD Shares Are Trading Higher Today (Benzinga) +36.56%
09:43AM	TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA® (Business Wire)
May-16-22 08:00PM	TherapeuticsMD, Inc. (TXMD) Q1 2022 Earnings Call Transcript (Motley Fool) -14.01%
05:45PM	TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	TherapeuticsMD Announces First Quarter 2022 Financial Results (Business Wire)
May-12-22 05:25PM	Harpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -13.87%
May-10-22 04:05PM	TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022 (Business Wire) -24.78%
Apr-14-22 04:15PM	TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million (Business Wire)
Mar-10-22 01:30PM	TherapeuticsMD, Inc. (TXMD) Q4 2021 Earnings Call Transcript (Motley Fool) -27.50%
08:05AM	TherapeuticsMD (TXMD) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
06:50AM	TherapeuticsMD Announces Fourth Quarter 2021 Financial Results (Business Wire)
Mar-07-22 12:57PM	TherapeuticsMD Shares Soars After VitaCare Divestiture In $150M Deal (Benzinga) +43.05%
07:40AM	TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx (Business Wire)
Mar-01-22 04:30PM	TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022 (Business Wire) -5.69%
Feb-28-22 05:35PM	Nektar Therapeutics (NKTR) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +8.28%
Feb-24-22 09:05AM	Radius Health (RDUS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Jan-25-22 08:52AM	TherapeuticsMD, Inc. (NASDAQ:TXMD): Is Breakeven Near? (Simply Wall St.)
Jan-06-22 07:29AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Jan-04-22 06:20AM	FDA Approves TherapeuticsMD's Low Dose Bijuva (Benzinga) +11.18%
Dec-28-21 09:53AM	Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options (Zacks)
Dec-13-21 06:08AM	TherapeuticsMD's Birth Control Med Receives FDA Response Letter To Revise Manufacturing Testing Limits (Benzinga) -11.51%
Dec-10-21 04:30PM	U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA® (Business Wire)
Dec-08-21 06:50AM	TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) Allowing for a May 25, 2032 Generic Entry Date (Business Wire)
Nov-24-21 07:54AM	TherapeuticsMD (NASDAQ:TXMD) investors are sitting on a loss of 90% if they invested five years ago (Simply Wall St.)
Nov-22-21 10:40AM	Therapeuticsmd Insider Trades $580K In Company Stock (Benzinga)
Nov-12-21 03:00AM	TherapeuticsMD, Inc. (TXMD) Q3 2021 Earnings Call Transcript (Motley Fool)
Nov-11-21 06:50AM	TherapeuticsMD Announces Third Quarter 2021 Financial Results (Business Wire) -7.82%
06:45AM	TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh ODowd, as Chief Executive Officer (Business Wire)
Nov-04-21 03:01PM	TherapeuticsMD (TXMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-27-21 05:00PM	TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021 (Business Wire)
Oct-15-21 05:33PM	TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer (Business Wire)
Oct-05-21 01:28PM	What Type Of Shareholders Own The Most Number of TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares? (Simply Wall St.)
Oct-04-21 09:20AM	Where Do Hedge Funds Stand On TherapeuticsMD Inc (TXMD)? (Insider Monkey)
Sep-02-21 06:50AM	Therapeutics MD Is Urging Women to Take Pause During Menopause Awareness Month (Business Wire) +7.71%
Aug-23-21 06:50AM	TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector (Business Wire) +7.12%
Aug-19-21 08:01AM	5 Penny Stocks Insiders Are Buying (Benzinga) +5.53%
Aug-09-21 04:30PM	TherapeuticsMD Announces Appointment of Hugh ODowd as President (Business Wire)
Aug-04-21 08:05AM	TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -6.66%
06:50AM	TherapeuticsMD Announces Second Quarter 2021 Financial Results (Business Wire)
Jul-28-21 03:03PM	Will TherapeuticsMD (TXMD) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-26-21 06:50AM	TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021 (Business Wire)
Jul-06-21 11:49AM	10 Best Pharmaceutical Stocks to Buy According to Billionaire Joseph Edelman (Insider Monkey)
Jun-29-21 08:58AM	Breakeven On The Horizon For TherapeuticsMD, Inc. (NASDAQ:TXMD) (Simply Wall St.)
May-25-21 06:50AM	TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA (Business Wire)
May-24-21 07:00AM	The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Florida Top Workplaces 2021 Award (Business Wire)
May-07-21 01:31AM	TherapeuticsMD, Inc. (TXMD) Q1 2021 Earnings Call Transcript (Motley Fool)
May-06-21 10:56AM	TherapeuticsMD Shares Plunge On Declining Gross Margin, Total Prescription Volume (Benzinga) -13.28%
08:20AM	TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	TherapeuticsMD Announces First Quarter 2021 Financial Results (Business Wire)
06:45AM	TherapeuticsMD, Inc. to Host Earnings Call (ACCESSWIRE)
May-03-21 07:00AM	TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting (Business Wire)
Apr-29-21 10:34AM	TherapeuticsMD's (NASDAQ:TXMD) Shareholders Are Down 85% On Their Shares (Simply Wall St.)
07:00AM	TherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021 (Business Wire)
Apr-28-21 12:34PM	TherapeuticsMD (TXMD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-09-21 11:16AM	TXMD Stock: The News Giving TherapeuticsMD Shares a Shot in the Arm Friday (InvestorPlace)
05:05AM	TherapeuticsMD's Hormone Therapy Approved in U.K. and Belgium (TheStreet.com)
Apr-08-21 04:05PM	TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium (Business Wire)
Mar-15-21 10:32AM	Here's What TherapeuticsMD, Inc.'s (NASDAQ:TXMD) Shareholder Ownership Structure Looks Like (Simply Wall St.)

TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thompson Tommy G	Director	Apr 14 '25	Buy	1.00	325	326	14,779	Apr 15 07:59 AM
Walker Marlan D	Chief Executive Officer	Apr 14 '25	Buy	1.00	490	489	73,639	Apr 15 07:59 AM
Walker Marlan D	Chief Executive Officer	Apr 10 '25	Buy	0.86	1,167	1,000	73,149	Apr 10 04:29 PM
Walker Marlan D	Chief Executive Officer	Apr 09 '25	Buy	0.87	1,136	994	71,982	Apr 10 04:29 PM
Collins Cooper C.	Director	Feb 18 '25	Option Exercise	0.00	8,500	0	60,516	Feb 20 09:08 PM
Naughton Gail K	Director	Feb 18 '25	Option Exercise	0.00	8,500	0	8,500	Feb 20 09:07 PM
Thompson Tommy G	Director	Feb 18 '25	Option Exercise	0.00	8,500	0	14,454	Feb 20 09:07 PM
Walker Marlan D	Chief Executive Officer	Feb 18 '25	Option Exercise	0.00	8,281	0	70,846	Feb 20 09:07 PM
Collins Cooper C.	Director	Aug 22 '24	Buy	1.73	4,094	7,099	52,016	Aug 26 05:40 PM
Collins Cooper C.	Director	Aug 21 '24	Buy	1.70	1,200	2,039	47,922	Aug 23 06:18 PM

Dollar change +0.10
Percentage change 0.03	%

UTHR United Therapeutics Corp daily Stock Chart

Peers: AMGN PFE LLY MRK REGN JNJ BMY VRTX GILD BIIB

| Held by: IJH VTI VB VBR VXF XBI MDY IBB IJK COWZ

Index	-	P/E	11.95	EPS (ttm)	24.60	Insider Own	1.83%	Shs Outstand	44.83M	Perf Week	0.88%
Market Cap	13.26B	Forward P/E	9.94	EPS next Y	29.58	Insider Trans	-29.29%	Shs Float	44.09M	Perf Month	-5.86%
Income	1.20B	PEG	1.84	EPS next Q	7.35	Inst Own	100.51%	Short Float	3.77%	Perf Quarter	-16.29%
Sales	2.88B	P/S	4.61	EPS this Y	13.13%	Inst Trans	2.96%	Short Ratio	3.26	Perf Half Y	-16.68%
Book/sh	143.74	P/B	2.05	EPS next Y	6.11%	ROA	16.32%	Short Interest	1.66M	Perf Year	25.44%
Cash/sh	72.43	P/C	4.06	EPS next 5Y	6.49%	ROE	19.23%	52W Range	253.93 - 417.82	Perf YTD	-16.69%
Dividend Est.	-	P/FCF	12.30	EPS past 5Y	-	ROI	18.55%	52W High	-29.65%	Beta	0.58
Dividend TTM	-	Quick Ratio	5.03	Sales past 5Y	14.94%	Gross Margin	89.24%	52W Low	15.76%	ATR (14)	11.87
Dividend Ex-Date	-	Current Ratio	5.25	EPS Y/Y TTM	25.66%	Oper. Margin	47.86%	RSI (14)	46.48	Volatility	4.15% 4.59%
Employees	1305	Debt/Eq	0.05	Sales Y/Y TTM	23.63%	Profit Margin	41.53%	Recom	1.80	Target Price	401.80
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	41.92%	Payout	0.00%	Rel Volume	0.88	Prev Close	293.85
Sales Surprise	8.92%	EPS Surprise	-0.99%	Sales Q/Q	19.72%	Earnings	Apr 30 BMO	Avg Volume	509.32K	Price	293.95
SMA20	1.31%	SMA50	-4.04%	SMA200	-14.68%	Trades		Volume	382,099	Change	0.03%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-21-25	Upgrade	BofA Securities	Underperform → Neutral	$314
Jul-11-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$310 → $321
Feb-12-24	Upgrade	Goldman	Sell → Neutral	$213 → $215
Feb-05-24	Initiated	Leerink Partners	Outperform	$330
Dec-08-23	Initiated	Wells Fargo	Overweight	$309
Dec-06-22	Initiated	UBS	Buy	$320
Dec-05-22	Initiated	Goldman	Sell	$230
Oct-11-22	Initiated	Morgan Stanley	Overweight	$288
Sep-20-22	Reiterated	BofA Securities	Underperform
Sep-19-22	Resumed	Wedbush	Outperform	$263
Feb-11-22	Initiated	BTIG Research	Neutral
Jul-14-21	Upgrade	Argus	Hold → Buy	$205
Apr-26-21	Resumed	Credit Suisse	Outperform	$196
Feb-01-21	Upgrade	H.C. Wainwright	Neutral → Buy	$125 → $195
Sep-14-20	Resumed	JP Morgan	Overweight	$142
Jun-25-20	Reiterated	H.C. Wainwright	Neutral	$85 → $125
Mar-10-20	Upgrade	Jefferies	Hold → Buy	$123
Feb-27-20	Upgrade	Cowen	Market Perform → Outperform	$119 → $145
Jan-31-20	Upgrade	JP Morgan	Neutral → Overweight	$120

Show Previous Ratings

Today 07:15AM	The Top 3 Stock Picks at the World's Greatest Hedge Fund (MarketBeat)
May-01-25 07:57AM	UTHR Q1 Earnings & Revenues Beat Estimates on Higher Tyvaso Sales (Zacks)
03:10AM	United Therapeutics Corp (UTHR) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
12:37AM	1 Value Stock Worth Investigating and 2 to Brush Off (StockStory)
12:34AM	Q1 2025 United Therapeutics Corp Earnings Call (Thomson Reuters StreetEvents)
01:09PM	Loading…
Apr-30-25 01:09PM	United Therapeutics Corporation (UTHR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	United Therapeutics (UTHR) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
07:35AM	United Therapeutics (UTHR) Q1 Earnings and Revenues Top Estimates (Zacks)
06:35AM	United Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
06:30AM	United Therapeutics Corporation Reports First Quarter 2025 Financial Results (Business Wire)
Apr-29-25 03:10AM	United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Apr-28-25 10:00AM	Neurocrine Biosciences (NBIX) Q1 Earnings Preview: What's in the Cards? (Zacks)
Apr-23-25 10:01AM	United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-22-25 03:27AM	Polaris Global Equity Composite Q1 2025 Commentary (Seeking Alpha)
Apr-21-25 07:00AM	United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference (Business Wire)
07:00AM	Loading…
Apr-16-25 07:00AM	United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025 (Business Wire)
Apr-11-25 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Apr-10-25 08:50AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Apr-08-25 12:10PM	Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Apr-07-25 06:38AM	Liquidia: United Therapeutics Has The Last Laugh (Seeking Alpha)
05:11AM	Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4 (StockStory)
Apr-04-25 07:00AM	United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions (Business Wire)
Apr-02-25 12:00PM	United Therapeutics Named to 100 Best Companies to Work For in 2025 by Fortune Media and Great Place to Work (Business Wire)
09:47AM	Is United Therapeutics Corporation (UTHR) The Most Profitable Biotech Stock To Buy Right Now? (Insider Monkey)
Mar-29-25 08:17AM	United Therapeutics: Don't Fear The Patent Expiration Too Much (Seeking Alpha)
Mar-28-25 06:48PM	Is United Therapeutics (UTHR) The Most Expensive Stock Insiders Are Dumping In March? (Insider Monkey)
11:30AM	United Therapeutics (UTHR) Down 4.8% Since Last Earnings Report: Can It Rebound? (Zacks)
05:10AM	3 Reasons Investors Watch United Therapeutics (UTHR) (StockStory)
Mar-21-25 04:47PM	Investing Action Plan: Anduril Industries, United Therapeutics, Barstool In Miami (Investor's Business Daily)
09:01AM	Loading…
Mar-18-25 09:01AM	2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off (StockStory)
Mar-14-25 12:11PM	Is United Therapeutics Corporation (UTHR) the Best Healthcare Stock For Long-Term Investment? (Insider Monkey)
Mar-12-25 12:44PM	2 Value Stocks on Our Watchlist and 1 to Ignore (StockStory)
Mar-04-25 07:00AM	United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025 (Business Wire)
Feb-28-25 11:35AM	United Therapeutics price target lowered to $420 from $430 at Leerink (TipRanks)
Feb-27-25 02:11AM	United Therapeutics Corp (UTHR) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Feb-26-25 11:35PM	Q4 2024 United Therapeutics Corp Earnings Call (Thomson Reuters StreetEvents) -10.80%
01:31PM	Why United Therapeutics (UTHR) Stock Is Down Today (StockStory)
09:30AM	United Therapeutics (UTHR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:57AM	United Therapeutics (NASDAQ:UTHR) Reports Q4 In Line With Expectations (StockStory)
07:35AM	United Therapeutics (UTHR) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
06:48AM	United Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
06:30AM	United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-25-25 08:03AM	What To Expect From United Therapeuticss (UTHR) Q4 Earnings (StockStory)
Feb-24-25 09:16AM	Seeking Clues to United Therapeutics (UTHR) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
07:00AM	United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-23-25 01:22PM	United Therapeutics Corporation (UTHR): Among Renaissance Technologies Portfolios Top Stock Picks (Insider Monkey)
Feb-19-25 07:00AM	United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025 (Business Wire)
Feb-14-25 04:05AM	United Therapeutics (UTHR): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Feb-13-25 10:13AM	Strength Seen in United Therapeutics (UTHR): Can Its 4.9% Jump Turn into More Strength? (Zacks)
Feb-12-25 06:20AM	United Therapeutics Corporation (UTHR): A Cheap Biotech Stock to Invest In Now (Insider Monkey)
Feb-04-25 07:00AM	United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis (Business Wire)
Feb-03-25 05:19PM	FDA Greenlights Studies of Pig Kidney Transplants in Humans (Bloomberg)
07:00AM	United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial (Business Wire)
Jan-28-25 03:00PM	Drugmakers Show Restraint on Price Increases in New Trump Era (The Wall Street Journal)
Jan-21-25 07:00AM	United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress (Business Wire)
Jan-10-25 09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks)
Jan-09-25 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
09:40AM	Are Medical Stocks Lagging United Therapeutics (UTHR) This Year? (Zacks)
Jan-06-25 07:00AM	United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-28-24 04:36PM	United Therapeutics Corporation (UTHR): Among the Cheap Healthcare Stocks to Buy Heading Into 2025 (Insider Monkey)
Dec-25-24 09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
Dec-24-24 11:50AM	Is United Therapeutics (UTHR) the Best Performing Biotech Stock in 2024? (Insider Monkey)
Dec-23-24 09:40AM	Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term (Zacks)
08:38AM	Here are Updates on United Therapeutics Corp. (UTHR) (Insider Monkey)
Dec-17-24 07:00AM	United Therapeutics Announces Successful World's First UKidney Transplant (Business Wire)
Nov-29-24 11:32AM	Why Is United Therapeutics (UTHR) Up 1.1% Since Last Earnings Report? (Zacks)
Nov-05-24 04:30PM	United Therapeutics Corporation to Present at the UBS Global Healthcare Conference (Business Wire)
09:45AM	United Therapeutics (UTHR) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
Nov-04-24 09:40AM	United Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Oct-31-24 04:46PM	Analyst Report: United Therapeutics Corporation (Morningstar Research)
03:08AM	United Therapeutics Corp (UTHR) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
01:11AM	Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insight (GuruFocus.com)
12:10AM	Q3 2024 United Therapeutics Corp Earnings Call (Thomson Reuters StreetEvents)
Oct-30-24 09:30AM	Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q3 Earnings (Zacks)
07:40AM	United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates (Zacks)
06:37AM	United Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	United Therapeutics Corporation Reports Third Quarter 2024 Financial Results (Business Wire)
Oct-29-24 09:15AM	Curious about United Therapeutics (UTHR) Q3 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Oct-23-24 07:00AM	United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service (Business Wire)
06:30AM	United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024 (Business Wire)
Oct-18-24 10:51AM	Profitable Biotech In Buy Zone As Earnings Approach (Investor's Business Daily)
Oct-16-24 05:01PM	State Street Corp's Strategic Reduction in United Therapeutics Holdings (GuruFocus.com)
Oct-09-24 03:31PM	United Therapeutics Corp (UTHR) Q2 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
07:56AM	Can United Therapeutics Corporation (UTHR) Capitalize on Record Revenue to Drive Future Growth? (Insider Monkey)
Oct-03-24 07:36AM	United Therapeutics Corporation (UTHR): Why Are Hedge Funds Bullish On This Cheap Growth Stock Right Now? (Insider Monkey)
Sep-24-24 07:00AM	United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting (Business Wire)
Sep-21-24 09:22AM	United Therapeutics (UTHR) Is Thriving on Strong Demand and Smart Pricing (Insider Monkey)
Sep-10-24 07:00AM	United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left BehindEver (Business Wire)
Aug-30-24 12:02PM	United Therapeutics Shares Thrive (FX Empire)
11:31AM	United Therapeutics (UTHR) Up 9.9% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-28-24 07:00AM	United Therapeutics Corporation to Present at Upcoming Investor Conferences (Business Wire)
Aug-22-24 07:01PM	Insider Sale: Director Christopher Causey Sells Shares of United Therapeutics Corp (UTHR) (GuruFocus.com)
Aug-21-24 07:08PM	Analyst Report: United Therapeutics Corporation (Morningstar Research)
Aug-20-24 06:33AM	Liquidias YUTREPIA inhalation powder gains tentative FDA approval (Pharmaceutical Technology)
Aug-19-24 04:01PM	Why Liquidia Stock Just Reversed Its Seven-Day Sprint And Crashed 31% (Investor's Business Daily) +8.60%
Aug-05-24 07:01PM	Insider Sale: Director Raymond Dwek Sells 5,000 Shares of United Therapeutics Corp (UTHR) (GuruFocus.com)
Aug-04-24 01:33PM	3 Biotech Stocks on Track for 50% Returns (or More) by 2028 (InvestorPlace)
Aug-02-24 12:00PM	United Therapeutics (UTHR) is a Great Momentum Stock: Should You Buy? (Zacks)
09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks)

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PAUL MAHON	Officer	May 01 '25	Proposed Sale	300.93	11,000	3,310,200		May 01 04:04 PM
DWEK RAYMOND	Director	Apr 21 '25	Option Exercise	175.43	3,000	526,290	4,750	Apr 22 04:30 PM
DWEK RAYMOND	Director	Apr 21 '25	Sale	285.57	3,000	856,710	1,750	Apr 22 04:30 PM
RAYMOND DWEK	Officer	Apr 21 '25	Proposed Sale	285.57	3,000	856,710		Apr 21 04:00 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Apr 17 '25	Option Exercise	117.76	11,000	1,295,360	47,781	Apr 18 04:31 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Apr 17 '25	Sale	283.78	11,000	3,121,543	36,781	Apr 18 04:31 PM
PAUL MAHON	Officer	Apr 17 '25	Proposed Sale	283.78	11,000	3,121,543		Apr 17 04:00 PM
DWEK RAYMOND	Director	Apr 14 '25	Option Exercise	175.43	3,000	526,290	4,750	Apr 15 04:28 PM
DWEK RAYMOND	Director	Apr 14 '25	Sale	285.16	3,000	855,480	1,750	Apr 15 04:28 PM
RAYMOND DWEK	Director	Apr 14 '25	Proposed Sale	285.16	3,000	855,480		Apr 14 04:02 PM
DWEK RAYMOND	Director	Apr 07 '25	Option Exercise	175.43	4,000	701,720	5,750	Apr 08 04:30 PM
DWEK RAYMOND	Director	Apr 07 '25	Sale	284.55	4,000	1,138,200	1,750	Apr 08 04:30 PM
RAYMOND DWEK	Director	Apr 07 '25	Proposed Sale	284.55	4,000	1,138,200		Apr 07 04:01 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Apr 03 '25	Option Exercise	117.76	11,000	1,295,360	47,781	Apr 07 09:05 AM
MAHON PAUL A	EVP & GENERAL COUNSEL	Apr 03 '25	Sale	306.18	11,000	3,367,984	36,781	Apr 07 09:05 AM
PAUL MAHON	Officer	Apr 03 '25	Proposed Sale	306.18	11,000	3,367,983		Apr 03 04:01 PM
Thompson Tommy G	Director	Mar 24 '25	Option Exercise	175.43	2,500	438,575	10,980	Mar 25 04:31 PM
Thompson Tommy G	Director	Mar 24 '25	Sale	318.80	2,500	796,990	8,480	Mar 25 04:31 PM
TOMMY THOMPSON	Director	Mar 24 '25	Proposed Sale	318.80	2,500	796,990		Mar 24 04:47 PM
PATUSKY CHRISTOPHER	Director	Mar 19 '25	Option Exercise	175.43	5,000	877,150	5,900	Mar 20 06:11 PM
PATUSKY CHRISTOPHER	Director	Mar 19 '25	Sale	310.72	5,000	1,553,585	900	Mar 20 06:11 PM
CHRISTOPHER PATUSKY	Director	Mar 19 '25	Proposed Sale	310.72	5,000	1,553,584		Mar 19 04:11 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Mar 10 '25	Option Exercise	111.00	2,000	222,000	2,000	Mar 11 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Mar 10 '25	Sale	320.09	2,000	640,184	0	Mar 11 04:30 PM
Michael Benkowitz	Officer	Mar 10 '25	Proposed Sale	315.91	1,679	530,413		Mar 10 04:23 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Mar 06 '25	Option Exercise	163.30	6,550	1,069,615	43,331	Mar 07 04:33 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Mar 03 '25	Option Exercise	111.00	9,679	1,074,369	7,179	Mar 04 04:41 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Mar 03 '25	Sale	311.99	9,679	3,019,736	0	Mar 04 04:41 PM
KURZWEIL RAY	Director	Feb 28 '25	Option Exercise	175.43	15,000	2,631,450	27,080	Mar 03 04:31 PM
KURZWEIL RAY	Director	Feb 28 '25	Sale	317.01	15,000	4,755,151	12,080	Mar 03 04:31 PM
Thompson Tommy G	Director	Feb 28 '25	Option Exercise	175.43	2,500	438,575	10,980	Mar 03 04:30 PM
Thompson Tommy G	Director	Feb 28 '25	Sale	318.34	2,500	795,838	8,480	Mar 03 04:30 PM
TOMMY THOMPSON	Director	Feb 28 '25	Proposed Sale	318.34	2,500	795,838		Feb 28 04:34 PM
RAYMOND KURZWEIL	Director	Feb 28 '25	Proposed Sale	317.01	15,000	4,755,152		Feb 28 04:26 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 24 '25	Option Exercise	111.00	10,000	1,110,000	7,500	Feb 25 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 24 '25	Sale	360.76	10,000	3,607,555	0	Feb 25 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Feb 20 '25	Option Exercise	163.30	7,700	1,257,410	44,410	Feb 21 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 18 '25	Option Exercise	111.00	10,000	1,110,000	7,500	Feb 19 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 18 '25	Sale	371.05	10,000	3,710,499	0	Feb 19 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 10 '25	Option Exercise	111.00	10,000	1,110,000	7,500	Feb 11 04:32 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 10 '25	Sale	348.06	10,000	3,480,642	0	Feb 11 04:32 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Feb 06 '25	Option Exercise	163.30	7,700	1,257,410	44,410	Feb 10 04:30 PM
Michael Benkowitz	Officer	Feb 10 '25	Proposed Sale	347.71	40,000	13,908,400		Feb 10 04:28 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 03 '25	Option Exercise	111.00	10,000	1,110,000	7,500	Feb 04 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 03 '25	Sale	353.64	10,000	3,536,398	0	Feb 04 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 27 '25	Option Exercise	111.00	10,000	1,110,000	7,500	Jan 28 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 27 '25	Sale	370.71	10,000	3,707,081	0	Jan 28 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 21 '25	Option Exercise	111.00	10,000	1,110,000	7,500	Jan 22 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 21 '25	Sale	364.91	10,000	3,649,112	0	Jan 22 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jan 16 '25	Option Exercise	163.30	7,700	1,257,410	44,410	Jan 17 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 13 '25	Option Exercise	111.00	10,000	1,110,000	7,500	Jan 14 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 13 '25	Sale	364.62	10,000	3,646,223	0	Jan 14 04:31 PM
PATUSKY CHRISTOPHER	Director	Jan 10 '25	Option Exercise	175.43	5,000	877,150	5,900	Jan 13 04:30 PM
PATUSKY CHRISTOPHER	Director	Jan 10 '25	Sale	361.61	5,000	1,808,072	900	Jan 13 04:30 PM
Michael Benkowitz	Officer	Jan 13 '25	Proposed Sale	364.97	40,000	14,598,800		Jan 13 04:30 PM
CHRISTOPHER PATUSKY	Director	Jan 10 '25	Proposed Sale	361.61	5,000	1,808,072		Jan 10 04:29 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 06 '25	Option Exercise	111.00	10,000	1,110,000	7,500	Jan 07 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 06 '25	Sale	355.15	10,000	3,551,517	0	Jan 07 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jan 02 '25	Option Exercise	163.30	7,700	1,257,410	44,410	Jan 03 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 30 '24	Option Exercise	111.00	10,000	1,110,000	7,500	Dec 31 04:32 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 30 '24	Sale	356.68	10,000	3,566,800	0	Dec 31 04:32 PM
Mesa Nilda	Director	Dec 30 '24	Sale	355.77	255	90,720	5,528	Dec 31 04:31 PM
NILDA MESA	Director	Dec 30 '24	Proposed Sale	355.77	255	90,720		Dec 30 04:08 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 23 '24	Option Exercise	111.00	10,000	1,110,000	7,500	Dec 26 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 23 '24	Sale	361.95	10,000	3,619,535	0	Dec 26 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 19 '24	Option Exercise	163.30	7,700	1,257,410	44,410	Dec 20 04:31 PM
SULLIVAN LOUIS W	Director	Dec 18 '24	Option Exercise	175.43	15,000	2,631,450	31,260	Dec 19 04:30 PM
SULLIVAN LOUIS W	Director	Dec 18 '24	Sale	373.22	26,209	9,781,715	5,051	Dec 19 04:30 PM
LOUIS W. SULLIVAN	Director	Dec 18 '24	Proposed Sale	373.28	26,209	9,783,214		Dec 18 05:51 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 16 '24	Option Exercise	111.00	10,000	1,110,000	7,500	Dec 17 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 16 '24	Sale	370.14	10,000	3,701,377	0	Dec 17 04:31 PM
Michael Benkowitz	Officer	Dec 16 '24	Proposed Sale	361.81	40,000	14,472,400		Dec 16 04:38 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 09 '24	Option Exercise	107.00	10,000	1,069,995	4,500	Dec 10 04:32 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 09 '24	Sale	367.69	10,000	3,676,877	0	Dec 10 04:32 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 05 '24	Option Exercise	163.30	7,700	1,257,410	44,410	Dec 06 04:31 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 05 '24	Sale	374.37	7,700	2,882,649	36,710	Dec 06 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 02 '24	Option Exercise	104.33	10,000	1,043,325	7,500	Dec 03 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 02 '24	Sale	370.51	10,000	3,705,074	0	Dec 03 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 25 '24	Option Exercise	104.33	10,000	1,043,325	7,500	Nov 27 06:44 AM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 25 '24	Sale	372.75	10,000	3,727,547	0	Nov 27 06:44 AM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 21 '24	Option Exercise	163.30	7,700	1,257,410	44,410	Nov 22 05:37 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 21 '24	Sale	367.36	7,700	2,828,672	36,710	Nov 22 05:37 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 18 '24	Option Exercise	104.33	10,000	1,043,325	7,500	Nov 19 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 18 '24	Sale	359.21	10,000	3,592,071	0	Nov 19 04:30 PM
Michael Benkowitz	Officer	Nov 18 '24	Proposed Sale	363.25	40,000	14,530,000		Nov 18 05:04 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 11 '24	Option Exercise	104.33	15,000	1,564,988	11,250	Nov 12 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 11 '24	Sale	407.32	15,000	6,109,841	0	Nov 12 04:30 PM
Olian Judy D.	Director	Nov 11 '24	Sale	412.48	1,750	721,840	5,655	Nov 12 04:30 PM
Mesa Nilda	Director	Nov 08 '24	Sale	412.28	224	92,350	5,783	Nov 12 04:30 PM
JUDY OLIAN	Director	Nov 11 '24	Proposed Sale	412.48	1,750	721,840		Nov 12 11:32 AM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 07 '24	Option Exercise	163.30	7,700	1,257,410	44,410	Nov 08 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 07 '24	Option Exercise	104.33	15,000	1,564,988	11,250	Nov 08 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 06 '24	Option Exercise	112.50	10,000	1,125,000	7,500	Nov 08 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 07 '24	Sale	401.44	15,000	6,021,620	0	Nov 08 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Nov 06 '24	Sale	394.96	10,000	3,949,594	0	Nov 08 04:30 PM
NILDA MESA	Director	Nov 08 '24	Proposed Sale	412.28	224	92,350		Nov 08 04:17 PM
Michael Benkowitz	Officer	Nov 06 '24	Proposed Sale	382.77	40,000	15,310,800		Nov 06 05:07 PM
Giltner Richard	Director	Nov 05 '24	Option Exercise	175.43	10,000	1,754,300	27,420	Nov 06 04:30 PM
Giltner Richard	Director	Nov 05 '24	Sale	381.70	10,000	3,817,022	17,420	Nov 06 04:30 PM
RICHARD GILTNER	Director	Nov 05 '24	Proposed Sale	381.70	10,000	3,817,022		Nov 05 04:33 PM

TXMD

TherapeuticsMD Inc

UTHR

United Therapeutics Corp

Upgrade your FINVIZ experience